Novel lactic acid bacteria and use thereof for treating or preventing liver damage-related diseases

Abstract

The present invention provides a novel lactic acid bacteria and its use for treating or preventing liver damage-related diseases. Specifically, the novel lactic acid bacteria comprises Pediococcus pentosaceus TTL 3-14 and / or Lactobacillus paracasei subsp. paracasei TTL 6-2. When an effective amount of the novel lactic acid bacteria provided by the present invention is administered to an individual, the effect of treating or / and preventing alcohol-induced liver damage or fatty liver can be effectively achieved.

Description

Technical Field

[0001] The present invention relates to probiotics and uses thereof, and in particular to a novel lactic acid bacterium and uses thereof for treating or preventing liver damage-related diseases. Background Art

[0002] The liver is a very important part of the human digestive system, with functions such as absorption, metabolism and immune protection. Long-term chronic drinking behavior will affect the body's metabolism, causing triglycerides and cholesterol to accumulate in the liver, leading to fatty liver or other alcoholic liver diseases. Specifically, according to research, ethanol, a metabolite of alcohol, will change the permeability of intestinal epithelial cells and increase the production of bacterial toxins in the intestine, such as endotoxins, thereby inducing or aggravating liver disease.

[0003] Although fatty liver does not cause immediate harm to human health, it will damage liver cells in the long run and may cause irreversible diseases such as hepatitis, liver fibrosis, cirrhosis or liver cancer. Currently, there are no clinically available drugs to treat fatty liver. Fatty liver or its related metabolic diseases can only be controlled or improved by changing eating and living habits. However, the vast majority of patients are unable to change their living or eating habits for a long time, making the clinical treatment of fatty liver difficult.

[0004] Therefore, developing a composition that can effectively treat or prevent liver damage-related diseases is a top priority in current medical research. Summary of the invention

[0005] The main purpose of the present invention is to provide a novel lactic acid bacteria, which comprises Pediococcus pentosaceus TTL 3-14 and Lactobacillus paracasei subsp. paracasei TTL 6-2; and the novel lactic acid bacteria has the ability to increase the activity of liver antioxidant enzymes and reduce inflammatory factors, so as to effectively prevent or improve liver cell damage or related diseases, especially liver diseases caused by alcohol, such as fatty liver.

[0006] Specifically, the deposit information of Pediococcus pentosaceus TTL 3-14 is as follows: the deposit number is DSM 33844; the deposit date is February 24, 2021; the deposit unit is: German Collection of Microorganisms (DSMZ); the deposit location is Germany. The deposit information of Lactobacillus paracasei subsp. paracasei TTL 6-2 is as follows: the deposit number is DSM 33845; the deposit date is February 24, 2021; the deposit unit is: German Collection of Microorganisms (DSMZ); the deposit location is Germany.

[0007] Another object of the present invention is to provide a composition comprising an effective amount of the novel lactic acid bacteria provided by the present invention, and administering the composition to a subject can effectively improve or prevent liver damage, fatty liver or diseases related to the above symptoms.

[0008] Specifically, the composition provided in one embodiment of the present invention comprises at least one lactic acid bacterium, and the lactic acid bacterium is Pediococcus pentosaceus TTL 3-14 or Lactobacillus paracasei subsp. paracasei TTL 6-2.

[0009] In order to achieve better liver disease prevention and / or treatment effects, in another embodiment of the present invention, the composition comprises Pediococcus pentosaceus TTL 3-14 and Lactobacillus paracasei subsp. paracasei TTL 6-2.

[0010] In another embodiment of the present invention, the composition comprises another lactic acid bacteria, which is Lactobacillus plantarum subsp. plantarum TTL 8-16; preferably, the composition is a mixture of Pediococcus pentosaceus TTL 3-14, Lactobacillus paracasei subsp. paracasei TTL 6-2 and Lactobacillus plantarum subsp. plantarum TTL 8-16 in an equal weight ratio.

[0011] In an embodiment of the present invention, the composition can be prepared as a food or a nutritional supplement, and can be prepared into different dosage forms, such as powder, tablets, etc., according to needs.

[0012] In another embodiment of the present invention, the novel lactic acid bacteria provided by the present invention are used to treat or prevent liver damage-related diseases, that is, when an effective amount of the novel lactic acid bacteria provided by the present invention or a composition containing the same is administered to an individual, the effect of preventing and / or treating alcoholic liver damage or its related diseases can be effectively achieved.

[0013] Among them, the alcoholic liver damage is fatty liver.

[0014] The composition is a liver antioxidant enzyme activity promoter, which can enhance the activity of glutathione and glutathione peroxidase, strengthen the liver's antioxidant capacity, and achieve the effect of avoiding or improving liver tissue damage.

[0015] The beneficial effects of the present invention are:

[0016] The present invention provides a novel lactic acid bacterium, which has the ability to increase the activity of liver antioxidant enzymes and reduce inflammatory factors, so as to effectively prevent or improve liver cell damage or related diseases, especially liver diseases caused by alcohol, such as fatty liver. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The relative clearance rate of AST was detected and analyzed after different treatments of HepG2 cells in each group.

[0018] Figure 2 The relative clearance rate of ALT was detected and analyzed after different treatments of HepG2 cells in each group.

[0019] Figure 3 To record the weight changes of mice in each group at 0, 2, 4, 6, and 8 weeks of the experiment.

[0020] Figure 4 To record the results of AST activity in the serum of each group of mice at 0, 2, 4, 6, and 8 weeks of the experiment.

[0021] Figure 5 To record the results of ALT activity in the serum of each group of mice at 0, 2, 4, 6, and 8 weeks of the experiment.

[0022] Figure 6 To record the results of serum cholesterol levels in each group of mice at 0, 2, 4, 6, and 8 weeks of the experiment.

[0023] Figure 7 To record the results of serum triglyceride levels in each group of mice at 0, 2, 4, 6, and 8 weeks of the experiment.

[0024] Figure 8 The results are for detecting the triglyceride content in the liver of each group of mice.

[0025] Fig. 9 These are the results of detecting glutathione activity in the liver of each group of mice.

[0026] Fig.10 These are the results of detecting the activity of glutathione peroxidase in the liver of mice in each group.

[0027] Fig.11 The results of H&E staining of liver tissue sections from group 1 mice.

[0028] Fig.12 The results of H&E staining of liver tissue sections from group 2 mice.

[0029] Fig.13 The results of H&E staining of liver tissue sections from group 3 mice.

[0030] Fig.14 The results of H&E staining of liver tissue sections from group 4 mice.

[0031] Fig.15 The results of H&E staining of liver tissue sections from group 5 mice.

[0032] Fig.16 The results of H&E staining of liver tissue sections from group 6 mice. DETAILED DESCRIPTION

[0033] The novel lactic acid bacteria provided by the present invention include strains TTL 3-14 and TTL 6-2, which are isolated from cereal sources and have basic properties of probiotics, such as acid resistance, bile resistance, and intestinal epithelial cell adsorption, and will not cause harm to organisms; wherein:

[0034] The deposit number of strain TTL 3-14 is DSM 33844; the deposit date is February 24, 2021; the depository is: German Collection of Microorganisms (DSMZ); strain TTL 3-14 is a Gram-positive cocci, does not have catalase, oxidase and motility characteristics, does not produce endospores, and can grow under both aerobic and anaerobic conditions.

[0035] The deposit number of strain TTL 6-2 is DSM 33845; the deposit date is February 24, 2021; German Collection of Microorganisms (DSMZ); strain TTL 6-2 is a Gram-positive bacillus, does not have catalase, oxidase and motility characteristics, does not produce endospores, and can grow under both aerobic and anaerobic conditions.

[0036] The strains TTL 3-14 and TTL 6-2 provided by the present invention can be cultured under the following conditions: the culture medium is a lactic acid bacteria MRS culture medium (Lactobacilli MRS broth, BD, difco, USA) containing 0.05% L-cysteine, and cultured at 37°C for 16 hours; the storage conditions after culture are: MRS culture medium (MRS broth) containing 15% glycerol, and stored at -80°C.

[0037] The “strain TTL 3-14” referred to in the present invention is Pediococcus pentosaceus TTL 3-14 with a deposit number of DSM 33844.

[0038] The “strain TTL 6-2” referred to in the present invention is Lactobacillus paracasei subsp. paracasei TTL 6-2 with a deposit number of DSM 33845.

[0039] The "strain TTL 8-16" referred to in the present invention is Lactobacillus plantarum subsp. plantarum TTL 8-16; the depository is the German Collection of Microorganisms (DSMZ), the deposit date is April 23, 2020, the deposit number is DSM33508, and the deposit address is Germany; further, the TTL 8-16 strain is a Gram-positive bacillus, does not have catalase, oxidase and motility, does not produce endospores, and can grow in both aerobic and anaerobic environments.

[0040] The "lactic acid bacteria composition" referred to in the present invention refers to a mixture of cultured strains TTL 3-14, strains TTL 6-2 and strains TTL 8-16 in an equal weight ratio (1:1:1), wherein each of the strains may be washed with sterile phosphate buffer before mixing.

[0041] The term "effective amount" as used herein refers to the amount of a compound or active ingredient required to produce a desired specific effect, which may be expressed as a percentage of the weight of the composition. As is known to those skilled in the art, the effective amount may vary depending on the method of administration to induce a specific effect. Generally, the amount of the active ingredient or compound in the composition may be from about 1% to about 100% by weight of the composition, preferably from about 30% to about 100%.

[0042] In order to further illustrate the technical features and effects of the present invention, several embodiments are given below with accompanying diagrams for detailed description.

[0043] The strains used in the following examples were stored in MRS broth containing 15% glycerol and stored at -80° C. The strains were activated twice, the culture medium was Lactobacilli MRS broth (BD, difco, USA) containing 0.05% L-cysteine, and the culture condition was 37° C. for 24 hours.

[0044] The human liver cancer cells C3A (HepG2 / C3A) (Deposit No.: BCRC 60177) and mouse macrophage RAW264.7 used in the following examples are experimental cells. The human liver cancer cells C3A (HepG2 / C3A) (Deposit No.: BCRC 60177) and mouse macrophage RAW264.7 (Deposit No.: BCRC 60001) used are both cell lines that can be easily purchased by technicians in this field. The present invention was purchased from the Bioresource Conservation and Research Center of the Institute of Food Industry (Taiwan, China).

[0045] Example 1: In vitro anti-inflammatory test

[0046] Human hepatoma cell C3A (hereinafter referred to as HepG2 cells) and mouse macrophage RAW264.7 (hereinafter referred to as RAW264.7 cells) were cultured in 24-well plates, with 2 x 10 HepG2 cells in each well. 5 The cell number of cell / well and RAW264.7 cells is 1x 10 5 When the cells grew to 80%, they were washed with phosphate buffer, and then new culture medium was added. Then 100 μl of lipopolysaccharide (LPS, 100 ng / mL) and 100 μl of lactic acid bacteria solution were added. The number of cells was 10 9 CFU / mL, and then cultured in a carbon dioxide incubator for 24 hours, and the cell supernatant of each well was collected.

[0047] The supernatant collected from RAW264.7 cells was assayed for TNF-α and IL-6 using a commercially available enzyme-linked immunosorbent assay kit ELISA (purchased from BioLegend); and the supernatant collected from HepG2 cells was assayed for IL-8 using a commercially available enzyme-linked immunosorbent assay kit (BD OptEIA Set Human IL-8, purchased from BD Biosciences). The results are shown in Table 1 below, wherein the blank group was not added with LPS and lactic acid bacteria solution, and the LPS group was not added with lactic acid bacteria solution.

[0048] Table 1: Anti-inflammatory results of various lactic acid bacteria

[0049] Group TNF-α(pg / mL) IL-6 (pg / mL) IL-8 (pg / mL) Blank group 273.69 3.18 118.22 LPS group (100ng) 469.03 818.16 153.39 Strain TTL 3-14 1.73 4.04 1.09 Strain TTL 6-2 1.49 4.34 0.88 Strain TTL 8-16 1.43 4.34 12.51

[0050] From the results in Table 1, it can be seen that strains TTL 3-14, strain TTL 6-2 and strain TTL 8-16 can all reduce TNF-α and IL-6, but for Hep G2 cells that produce inflammatory hormones: IL-8 after LPS stimulation, only strains TTL 3-14 and strain TTL 6-2 can achieve significantly better inhibitory effects.

[0051] Since Hep G2 cells do not produce inflammatory factors such as IL-6, TNF-α and IFN-γ after being stimulated by LPS, but produce a large amount of IL-8, it can be clearly seen from Table 1 above that the strains TTL 3-14 and TTL 6-2 provided by the present invention can not only inhibit the inflammatory response in the body, but also have a good therapeutic or preventive effect on liver inflammation.

[0052] Example 2: In vitro alcohol tolerance test

[0053] Strain TTL 3-14, strain TTL 6-2, and strain TTL 8-16 were respectively taken, activated and cultured for 16 hours, and then 100 μl of the cultured bacterial solution was taken and inoculated into 4 mL MRS broth without alcohol, 4 mL MRS broth containing final alcohol concentrations of 1%, 5%, 10%, 15% and 20%, respectively, and then cultured at 37°C for 16 hours. The cultured bacterial solution was then serially diluted and the number of bacteria was calculated by plate count. The results are shown in Table 2 below.

[0054] Table 2: The number of bacteria obtained after the alcohol tolerance test of each lactic acid bacteria

[0055]

[0056] From the results in Table 2 above, it can be seen that strains TTL 3-14 and strain TTL 6-2 provided by the present invention can survive in an environment with high concentration of alcohol, among which strain TTL 6-2 has better tolerance to alcohol, that is, it can survive in an environment containing an alcohol concentration of more than 20%.

[0057] Example 3: Detection of biochemical indicators of alcoholic liver injury in vitro

[0058] HepG2 cells were cultured at 2 x 10 5 Cells were inoculated into 24-well plates. When the cells grew to 80%, they were washed with phosphate buffered saline and the culture medium was replaced with MEM medium without FBS. The cells were divided into groups and treated with different conditions:

[0059] The blank group was supplemented with 1 ml of culture medium;

[0060] The alcohol group was supplemented with 900 μl of culture medium;

[0061] The silymarin (SML) group was supplemented with 800 μl of culture medium, 100 μl of alcohol, the final alcohol concentration was 100 mM, and then 100 μl of silymarin (30 μg / mL);

[0062] After adding 800 μl of culture medium to each strain group, 100 μl of alcohol was added, with the final alcohol concentration being 100 mM, and then the lactic acid bacteria solution was added;

[0063] After each group was placed for 24 hours, the supernatant and cells were collected and the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were detected using a commercially available ALT analysis kit (purchased from BioVision) and AST analysis kit (purchased from BioVision), respectively. The results are shown in Figure 1 and Figure 2 .

[0064] Depend on Figure 1 and Figure 2 The results show that when HepG2 cells are stimulated by alcohol to produce ALT and AST, only the strains TTL 3-14 and TTL 6-2 provided by the present invention can simultaneously reduce the levels of ALT and AST, indicating that the strains TTL 3-14 and TTL 6-2 provided by the present invention have the effect of protecting the liver from inflammation or pathological changes caused by alcohol stimulation.

[0065] Example 4: Detection of serum biochemical index expression

[0066] Sixty seven-week-old C57BL / 6N male mice (Lesco Biotech, Taiwan, China) were purchased and housed in an environment with a temperature of 22±2°C, a relative humidity of 55±5%, and a light cycle of 12 hours. The feed used was a liquid general feed.

[0067] After the mice were raised for 1 week, they were randomly divided into groups and each group was raised for 8 weeks under the following treatment conditions. After the experiment was completed, the mice in each group were sacrificed and their livers were taken out for the experiments in the subsequent examples:

[0068] Group 1 (blank group): fed only with normal liquid feed without alcohol;

[0069] Group 2 (alcohol group): fed with liquid alcohol feed containing 36% alcohol (0.36 kcal / ml) of total calories;

[0070] Group 3 (strain TTL 3-14 group): fed with liquid alcohol feed containing 36% alcohol (0.36 kcal / ml) and a dose of 9 log CFU / ml of strain TTL 3-14;

[0071] Group 4 (strain TTL 6-2 group): fed with liquid alcohol feed containing 36% alcohol (0.36 kcal / ml) and a dose of 9 log CFU / ml of strain TTL 6-2;

[0072] Group 5 (strain TTL 8-16 group) was fed with liquid alcohol feed containing 36% alcohol (0.36 kcal / ml) and a dose of 9 log CFU / ml of strain TTL 8-16;

[0073] The sixth group (lactic acid bacteria composition group) was fed with a liquid alcohol feed containing 36% alcohol (0.36 kcal / ml) in total calories and a lactic acid bacteria composition at a dose of 9 log CFU / ml.

[0074] The weight of mice in each group was recorded and blood was collected from the eye sockets at 0, 2, 4, 6, and 8 weeks. The blood was tested for serum and analyzed for AST and ALT, triglycerides, and total cholesterol. The results are as follows: Figures 3 to 7 shown.

[0075] Depend on Figure 3 The results showed that during the experiment, when all groups of mice had a normal diet, the weight of the mice in Group 1 that were not fed with alcohol was heavier than that of the mice in other groups (P < 0.05), indicating that long-term feeding of alcohol can indeed induce alcoholic hepatitis or related symptoms in mice, causing the mice fed with alcohol to lose weight.

[0076] Furthermore, by Figure 4 and Figure 5 The results showed that the AST and ALT values ​​in the serum of the first group of mice hardly changed during the experiment; the AST and ALT values ​​in the serum of the second group of mice increased significantly as the alcohol feeding time became longer (the experimental period became longer) (P < 0.05), and compared with the first group of mice, the AST in the serum of the second group of mice increased significantly by 53% in the eighth week of the experiment; and at the eighth week of the experiment, the AST values ​​in the serum of the third, fourth and sixth groups of mice were significantly lower than those in the second group of mice, decreasing by 42%, 33% and 37% respectively (P < 0.05), and the ALT values ​​in the serum of the third and sixth groups of mice were significantly lower than those in the second group of mice, decreasing by 54% and 48% respectively (P < 0.05). According to the study, the increase in the AST and ALT values ​​in the serum indicates that the liver damage is more serious. Therefore, Figure 4 and Figure 5The results show that the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention has a specific therapeutic or preventive effect on liver damage or liver disease caused by alcohol, that is, when an effective amount of the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention is administered to a subject with a drinking habit, it can effectively improve or prevent alcoholic liver damage or liver disease.

[0077] Again, although by Figure 6 The results showed that there was no significant change in the total cholesterol content in the serum of each group of mice. Figure 7 The results showed that at the 4th week of the experiment, compared with the mice in the 2nd group, the triglyceride content in the serum of the mice in the 3rd and 4th groups was significantly reduced (P < 0.05), by 28.9% and 22.7%, respectively, and the reduction effect could be maintained until the end of the experiment (the 8th week); further, at the 4th week of the experiment, the triglyceride content in the serum of the mice in the 5th group decreased the most, by about 44.8% compared with the mice in the 3rd or 4th group, and the triglyceride content in the serum of the mice in the 6th group decreased by about 23.9%; after the 4th week of the experiment, except for the mice in the 2nd group, the triglyceride content in the serum of the mice in each group was almost the same as that of the mice in the 1st group (blank group), and at the 8th week of the experiment, the triglyceride content in the serum of the mice in the 5th and 6th groups continued to decrease, by about 35.4% and 34.4% respectively compared with the triglyceride in the serum of the mice in the 2nd group, which was significantly different from each other (P < 0.05). In other words, by Figure 7 The results show that under an alcoholic diet, the strains TTL 8-16 and / or strains TTL 3-14 and / or strains TTL 6-2 provided by the present invention can continuously and effectively reduce the level of triglycerides in serum, so as to achieve the effect of preventing or treating vascular diseases caused by alcohol.

[0078] Example 5: Detection of triglyceride content in the liver

[0079] The liver tissues of the mice in each group were homogenized and centrifuged respectively. The supernatant was taken and the prepared triglyceride enzyme reagent (Triglyceride Enzyme Mixture) was added. After the reaction, the OD530-550nm absorbance was measured. The OD value of the standard (0 mg / dl) was subtracted from the obtained OD value. The triglyceride content in the liver of each group of mice was calculated by linear regression analysis of the drawn standard curve. The results are as follows: Figure 8 shown.

[0080] Depend on Figure 8The results showed that after 8 weeks, the triglyceride content in the liver of group 2 mice increased significantly compared with that of group 1 mice, which means that alcoholic diet does lead to fat accumulation in the liver and induces the occurrence of fatty liver; and compared with group 2 mice, the triglyceride content in the liver of group 3 to group 6 mice decreased significantly, by 49.8%, 53.7%, 45.9% and 47.2% respectively.

[0081] From the results, it can be seen that the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention can indeed prevent the accumulation of triglycerides in the liver tissue under alcoholic diet, and if an effective amount of the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention is continuously administered to individuals with a habit of drinking, the triglyceride content in the liver can be maintained at a level similar to that of individuals without a habit of drinking.

[0082] Example 6: Detection of Antioxidant Enzyme Expression in Liver

[0083] The liver tissues of the mice in each group after the experiment in Example 1 were taken and homogenized and centrifuged, and the supernatant was taken. The activity of glutathione (GSH) and glutathione peroxidase (GPx) in the liver tissues of the mice in each group was detected by commercially available analysis kits (QuantiChromTM Glutathione Assay Kit and EnzyChromTM Glutathione Peroxidase Assay Kit). The results are as follows: Fig. 9 and Fig.10 shown.

[0084] Depend on Fig. 9 The results showed that after 8 weeks, the glutathione content in the liver of the 5th group of mice was not significantly different from that of the 1st group of mice (P>0.05); the glutathione content in the liver of the 2nd group of mice was significantly higher than that of the 1st group of mice (P<0.05), but there was no significant difference between the 6th group of mice (P>0.05); and compared with the 2nd group of mice, the glutathione content in the liver of the 3rd and 4th groups of mice increased significantly by 37% and 35% (P<0.05); and since glutathione is an antioxidant substance in the organism, the results show that the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention is indeed a special lactic acid strain that can enhance the antioxidant capacity of the liver, that is, when an effective amount of the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention is administered to an individual under an alcohol diet, it can effectively enhance the glutathione in the liver of the individual, thereby achieving the effect of increasing the antioxidant capacity of the individual.

[0085] Furthermore, by Fig.10The results show that, after 8 weeks, the glutathione peroxidase activity in the liver of the mice in the second group decreased by 31.9% compared with that in the mice in the first group; and compared with the mice in the second group, the glutathione peroxidase activity in the liver of the mice in the third to sixth groups increased (increased by 30.6%, 31.6%, 16.9% and 58.4%, respectively), but the increase in the glutathione peroxidase activity in the liver of the mice in the fifth group was not good, indicating that the administration of strain TTL 8-16 has limited effect on improving the antioxidant capacity of the liver of the individual, but the administration of strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention can indeed increase the glutathione peroxidase activity in the liver.

[0086] Depend on Fig. 9 and Fig.10 The results show that the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention are specific lactic acid bacteria that can enhance the antioxidant capacity of the liver, which means that administering an effective amount of strain TTL 3-14 and / or strain TTL 6-2 to individuals with a habit of drinking alcohol can achieve the effect of avoiding or improving liver damage or alcohol-induced liver-related diseases by increasing the antioxidant active substances and / or antioxidant enzymes in the liver.

[0087] Example 5: Liver tissue section staining results

[0088] The liver tissues of the mice in each group were taken after the experiment in Example 1, and were embedded in paraffin and sliced ​​for H&E staining. Figures 11 to 16 shown.

[0089] Depend on Fig.11 It can be seen that no obvious fat droplet accumulation was found in the liver sections of group 1 mice, and the cell nuclei were very complete; Fig.12 It can be seen that the liver sections of the second group of mice have obvious accumulation of fat droplets, indicating that long-term administration of alcohol will indeed cause fat accumulation in the liver and produce symptoms of fatty liver; from Figure 13 to Fig.16 The results of Groups 3 to 6 shown in the figure show that the administration of different lactic acid bacteria or lactic acid bacteria compositions can reduce the fat droplets in the liver, reduce fat accumulation in the liver, and prevent liver cell damage. Comparison of the results of staining of liver tissue sections from Groups 3 to 6 shows that the administration of the TTL 3-14 strain provided by the present invention can more effectively prevent fat accumulation in liver tissue.

[0090] From the above results, it can be seen that under an alcoholic diet, the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention can avoid or improve the accumulation of fat in the liver, and can protect liver cells from damage and maintain cell integrity; in other words, when an effective amount of the strain TTL 3-14 and / or strain TTL 6-2 provided by the present invention is administered to an individual, the effect of preventing or treating fatty liver or its related diseases can be effectively achieved.

Claims

1. A Pediococcus pentosaceus ( pediococcus pentosaceus ) TTL 3-14, characterized in that, The preservation number of Pediococcus pentosaceus TTL 3-14 is DSM 33844; the preservation date is February 24, 2021; the preservation unit is the German Microbiological Collection Center; and the address is Germany.

2. A Lactobacillus paracasei subsp. paracasei ( Lactobacillus paracasei subsp. paracasei ) TTL 6-2, characterized in that, The preservation number of Lactobacillus paracasei subspecies paracasei TTL 6-2 is DSM 33845; the preservation date is February 24, 2021; the preservation unit is the German Microbiological Collection Center; and the address is Germany.

3. A composition, characterized in that The method comprises the Pediococcus pentosaceus TTL 3-14 as claimed in claim 1 and / or the Lactobacillus paracasei subspecies paracasei TTL 6-2 as claimed in claim 2.

4. The composition according to claim 3, characterized in that The invention comprises the Pediococcus pentosaceus TTL 3-14 and the Lactobacillus paracasei subspecies paracasei TTL 6-2.

5. The composition according to claim 4, characterized in that Also contains Lactobacillus plantarum subsp. Lactobacillus plantarum subsp. plantarum ) TTL 8-16, the preservation unit of this plant lactobacillus plant subspecies TTL8-16 is the German Microbiological Collection Center, the preservation date is April 23, 2020, the preservation number is DSM33508, and the preservation address is Germany.

6. The composition according to claim 5, characterized in that The Pediococcus pentosaceus TTL 3-14, the Lactobacillus paracasei subspecies paracasei TTL 6-2 and the Lactobacillus plantarum subspecies plantarum TTL 8-16 are mixed in an equal weight ratio.

7. A use of lactic acid bacteria as a composition for treating and / or preventing alcoholic liver damage, characterized in that: The lactic acid bacteria are Pediococcus pentosaceus TTL 3-14 as claimed in claim 1 and / or Lactobacillus paracasei subsp. paracasei TTL 6-2 as claimed in claim 2; and the alcoholic liver damage is fatty liver.

8. The use according to claim 7, characterized in that The composition is a liver antioxidant enzyme activity promoter.

Images